Merus (NASDAQ:MRUS) Now Covered by Analysts at Piper Sandler

Analysts at Piper Sandler assumed coverage on shares of Merus (NASDAQ:MRUS - Get Free Report) in a report released on Thursday, MarketBeat.com reports. The brokerage set an "overweight" rating and a $84.00 price target on the biotechnology company's stock. Piper Sandler's price target indicates a potential upside of 108.96% from the stock's previous close.

MRUS has been the topic of several other reports. UBS Group began coverage on Merus in a report on Thursday, October 24th. They set a "buy" rating and a $72.00 price objective on the stock. Citigroup lifted their price objective on shares of Merus from $89.00 to $97.00 and gave the company a "buy" rating in a report on Monday, December 9th. The Goldman Sachs Group started coverage on Merus in a research report on Thursday, November 21st. They set a "buy" rating and a $73.00 price target on the stock. Guggenheim reissued a "buy" rating on shares of Merus in a report on Wednesday, February 12th. Finally, Wells Fargo & Company initiated coverage on Merus in a report on Friday, February 7th. They set an "overweight" rating and a $91.00 price objective for the company. One research analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $85.92.

Merus Stock Performance

Shares of MRUS traded down $0.10 during mid-day trading on Thursday, hitting $40.20. 362,709 shares of the company traded hands, compared to its average volume of 655,991. Merus has a 1 year low of $37.77 and a 1 year high of $61.61. The stock has a market cap of $2.75 billion, a price-to-earnings ratio of -10.18 and a beta of 1.11. The stock has a 50-day moving average price of $41.55 and a two-hundred day moving average price of $47.13.

Institutional Investors Weigh In On Merus

Several large investors have recently modified their holdings of the stock. Boxer Capital Management LLC purchased a new stake in shares of Merus during the 4th quarter worth about $79,895,000. Wellington Management Group LLP lifted its holdings in Merus by 73.6% in the third quarter. Wellington Management Group LLP now owns 2,887,514 shares of the biotechnology company's stock worth $144,260,000 after acquiring an additional 1,224,573 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in Merus by 56.8% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,125,000 shares of the biotechnology company's stock valued at $89,356,000 after purchasing an additional 770,000 shares during the last quarter. FMR LLC grew its position in Merus by 10.4% in the 3rd quarter. FMR LLC now owns 6,873,926 shares of the biotechnology company's stock valued at $343,421,000 after buying an additional 648,994 shares in the last quarter. Finally, Westfield Capital Management Co. LP acquired a new stake in shares of Merus in the third quarter valued at $30,399,000. Hedge funds and other institutional investors own 96.14% of the company's stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.